Legal & General Group Plc Purchases New Stake in DaVita Inc. $DVA

Legal & General Group Plc purchased a new stake in shares of DaVita Inc. (NYSE:DVA) in the second quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 90,009 shares of the company’s stock, valued at approximately $20,025,000.

A number of other large investors have also recently made changes to their positions in DVA. BlackRock Inc. bought a new stake in shares of DaVita during the second quarter worth about $547,520,000. Arrowstreet Capital Limited Partnership boosted its stake in DaVita by 114.9% during the 4th quarter. Arrowstreet Capital Limited Partnership now owns 1,190,000 shares of the company’s stock valued at $135,196,000 after purchasing an additional 636,191 shares during the last quarter. Bank of New York Mellon Corp acquired a new position in DaVita during the 2nd quarter valued at about $101,127,000. Norges Bank bought a new stake in DaVita during the 4th quarter worth approximately $49,164,000. Finally, Corient Private Wealth LLC raised its stake in shares of DaVita by 1,493.1% in the fourth quarter. Corient Private Wealth LLC now owns 358,299 shares of the company’s stock worth $40,706,000 after purchasing an additional 335,809 shares during the last quarter. 90.12% of the stock is owned by institutional investors.

DaVita Stock Performance

Shares of NYSE:DVA opened at $180.72 on Friday. DaVita Inc. has a fifty-two week low of $101.00 and a fifty-two week high of $247.49. The company’s 50-day moving average is $211.96 and its 200 day moving average is $183.05. The company has a market capitalization of $11.53 billion, a P/E ratio of 14.79, a price-to-earnings-growth ratio of 0.47 and a beta of 0.88.

DaVita (NYSE:DVA) last released its earnings results on Tuesday, August 4th. The company reported $4.02 earnings per share for the quarter, beating analysts’ consensus estimates of $3.88 by $0.14. DaVita had a net margin of 6.05% and a negative return on equity of 217.63%. The firm had revenue of $3.55 billion for the quarter, compared to analysts’ expectations of $3.50 billion. During the same period in the previous year, the company earned $2.95 earnings per share. The company’s quarterly revenue was up 5.2% on a year-over-year basis. DaVita has set its FY 2026 guidance at 14.100-15.200 EPS. As a group, research analysts predict that DaVita Inc. will post 14.57 earnings per share for the current year.

Insider Transactions at DaVita

In related news, insider Kathleen Alyce Waters sold 15,405 shares of the business’s stock in a transaction dated Monday, June 15th. The stock was sold at an average price of $208.40, for a total value of $3,210,402.00. Following the sale, the insider directly owned 109,194 shares in the company, valued at approximately $22,756,029.60. The trade was a 12.36% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 1.90% of the company’s stock.

Analysts Set New Price Targets

Several research analysts recently issued reports on DVA shares. Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating and set a $265.00 target price on shares of DaVita in a research report on Wednesday, August 5th. Weiss Ratings upgraded DaVita from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Wednesday, August 5th. TD Cowen raised shares of DaVita from a “hold” rating to a “buy” rating and lifted their price objective for the stock from $201.00 to $220.00 in a report on Friday, August 7th. Barclays upped their target price on shares of DaVita from $218.00 to $224.00 and gave the stock an “equal weight” rating in a research note on Wednesday, August 5th. Finally, Zacks Research lowered shares of DaVita from a “strong-buy” rating to a “hold” rating in a research report on Monday, July 6th. Four analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, DaVita presently has a consensus rating of “Hold” and an average target price of $221.75.

About DaVita

DaVita Inc (NYSE: DVA) is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.

Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.